Effects of High-dose Atorvastatin Pretreatment in Patients with ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Cardiac Magnetic Resonance Study

Eun Kyoung Kim,1 Joo-Yong Hahn,1 Young Bin Song,1 Sung-A Chang,1 Jin-Ho Choi,1 Seung-Hyuk Choi,1 Sang-Chol Lee,1 Yeon Hyeon Choe,2 Sang Hoon Lee,1 and Hyeon-Cheol Gwon1

1Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Cardiovascular Imaging Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul; 2Department of Radiology and Center for Imaging Science, Cardiovascular Imaging Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Received: 13 August 2014
Accepted: 6 November 2014

Address for Correspondence:
Joo-Yong Hahn, MD
Division of Cardiology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 135-710, Korea
Tel: +82.2-3410-6653, Fax: +82.2-3410-6279
E-mail: jyhahn@skku.edu

Funding: This study was supported by a grant from the Institute of Health and Society, Korea (CA88331).

INTRODUCTION

Since statins have a preventive role in primary and secondary prevention of coronary artery disease (1-3), several prospective trials have been conducted to identify the favorable effects of statin before percutaneous coronary intervention (PCI) (4-7). In those trials, atorvastatin pretreatment in patients undergoing PCI for stable angina and non-ST-segment elevation myocardial infarction reduced myocardial damage and improved clinical outcomes. However, it is uncertain whether pretreatment of high dose of statins in patients with ST-segment elevation myocardial infarction (STEMI) can reduce infarct size. To answer this question, we conducted a prospective randomized trial to evaluate the effects of atorvastatin pretreatment on infarct size in patients with STEMI (AT-STEMI) (8). In this study, pretreatment with high-dose atorvastatin followed by further treatment for 5 days did not reduce infarct size measured by single-photon emission computed tomography (SPECT). Although infarct size measured by SPECT has been reported to be a surrogate for clinical outcomes (9), contrast enhanced magnetic resonance imaging (CE-MRI) is superior to myocardial SPECT in measuring infarct size, especially when the infarct burden is small and nontransmural (10-12). In addition, CE-MRI can assess the area at risk (AAR), microvascular obstruction (MVO), and myocardial hemorrhage in patients with myocardial infarction (13-15). Therefore, we used CE-MRI to evaluate the efficacy of atorvastatin pretreatment in patients undergoing primary PCI for STEMI. This study is a prespecified substudy of the AT-STEMI trial.

MATERIALS AND METHODS

Study design and patients

The AT-STEMI trial was a prospective randomized, multicenter study designated to evaluate the impact of high-dose atorvastatin pretreatment on myocardial infarct size in patients under-
going primary PCI for STEMI (8). This trial was registered with ClinicalTrials.gov, NCT00610870. Patients from 5 major coronary intervention centers in Korea were enrolled between August 2007 and February 2009. Patients were eligible if they had STEMI less than 12 hr after symptom onset. STEMI was defined as ST-segment elevation of at least 1 mm in two or more continuous leads on the electrocardiogram (ECG). Exclusion criteria were cardiogenic shock, previous MI, chronic liver disease, and current statin use. We planned several subsudies including using MRI before initiation of the AT-STEMI trial. All patients enrolled at the Samsung Medical Center, one of the participating centers, were candidates for the MRI substudy.

**Study protocol and procedure**

The study protocol was described previously (8). Briefly, patients were randomly assigned to the atorvastatin group or the conventional primary PCI (control) group. Randomization was stratified by the hospitals and the location of infarction. In the atorvastatin group, 80 mg of atorvastatin was administered as early as possible after randomization. All patients received 300 mg aspirin and 600 mg clopidogrel before PCI if they had not previously taken these medications. Intravenous heparin was administered to maintain an activated clotting time of 300 sec. Glycoprotein IIb/IIIa receptor antagonist was used at the operator’s discretion. Coronary angiography and stent implantation were performed using standard interventional techniques. After the procedure, 80 mg atorvastatin was maintained for 5 days, and then the dose of atorvastatin was decreased to 10 mg/day for the atorvastatin group. In the control group, treatment of 10 mg atorvastatin was initiated the day after primary PCI. Thereafter, atorvastatin was titrated to reduce low-density lipoprotein cholesterol < 1.8 mM/L (70 mg/dL) in both groups. The myocardial band fraction of creatinine kinase (CK-MB) was measured before PCI, and every 8 hr for 2 days after the procedure. After 2 days, CK-MB was measured once daily until the level of enzyme was normalized. Twelve-lead ECGs were obtained before and at 60 min after the procedure (8).

**Data analysis**

Baseline characteristics, angiographic and procedural data, medication use, and outcome data were recorded and collected by dedicated research coordinators. ECG and angiographic data were analyzed independently at the angiographic core laboratory of the Samsung Medical Center (Seoul, Korea). The total ST-segment elevation was measured manually from leads exploring infarct area (16). Complete ST-segment resolution was defined as a decrease > 70% in ST-segment elevation by comparing before and 60 min after PCI. Evaluation of myocardial blush grade (MBG) was performed using the angiograms made at the end of the index procedures as previously described: 0 = absence of contrast opacification in the myocardial infarct zone or persistent staining without washout, 1 = minimal contrast opacification, 2 = reduced but clearly evident blush in the infarct zone compared to the ipsilateral or contralateral noninvolved epicardial vessels, and 3 = myocardial contrast filling equal to or greater than that seen in the noninvolved epicardial vessels (17).

**CE-MRI protocol and analysis**

Between days 5 and 14, CE-MRI consisting of cine, T2 weighted imaging, first pass perfusion and delayed enhancement imaging was performed. A 1.5 Tesla magnetic scanner (Achieva, Philips Medical Systems, Best, the Netherlands) was used (19, 20). Cine MRI images were obtained using a fast gradient echo sequence after scout and localized image acquisition. Slice thickness was set at 6 mm and short-axis images of the left ventricle (LV) were acquired from the apex to base. Temporal resolution was 25-30 frames per RR interval. T2-weighted MRI was performed in the cardiac short-axis using an inversion recovery fast-spin echo sequence. For the first pass images of contrast, a dose of 0.15 M/kg gadolinium-diethylenetriamine pentaaetic acid (Magnevist, Bayer Schering Pharma, Berlin, Germany) was injected intravenously followed by a saline flush. T1-weighted dynamic sequence was performed with 6 mm slice thickness, 40 × 40 cm field-of-view and 128 × 128 image matrix. Delayed enhancement and microvascular obstruction (MVO) were evaluated 15 min after the administration of gadolinium in 10-12 continuous slices of 6 mm thickness with a 4 mm interslice gap using a multi-shot turbo field echo breath-hold sequence with nonselective inversion. The inversion delay time was varied in the range of 200-300 ms using a Look-Locker system.

Image analysis was performed using commercial analysis software, Cardiovascular Angiographic Analysis System (CAAS MRV version 1.0, Pie Medical Imaging B.V., the Netherlands) (19, 20). Left ventricular volume and ejection fraction were measured by contouring the endocardial and epicardial border of myocardium in the short-axis images acquired at the end diastole and systole. Myocardial mass was calculated by multiplying the myocardial volume by myocardial density (1.05 g/mL). The infarct volume was quantified by manual drawing of the delayed hyperenhanced lesion within each segment of the short-axis images, multiplied by the slice thickness to include the entire LV. The volume of perfusion defect and MVO were calculated in same manner. The presence of myocardial hemorrhage, defined as a central core of hypointense signal within an area of increased T2 signal intensity, and myocardial AAR, defined as a myocardium with signal intensity greater than 2 SDs above the mean signal intensity of remote normal myocardium, were quantified in a T2-weighted image using a similar algorithm. Additionally, the myocardial salvage index was computed as follows: myocardial salvage index = (AAR-infarct size) × 100/AAR (18). The infarct transmurality for each segment was calculated by
dividing hyperenhanced area by the total area of affected myocardium. The transmural infarction was defined as the segments with > 75% of infarct transmurality (19, 20).

**Study end points**
The primary end point was myocardial infarct size as assessed by CE-MRI. The secondary end points included myocardial salvage index and MVO area assessed by CE-MRI. MBG, complete ST resolution, and peak CK-MB level after the procedure were also compared between the atorvastatin group and control group.

**Statistical analysis**
The expected standard deviation of myocardial infarct size was estimated to be 10% based on the previous study (21), and a difference > 7.5% would be regarded as significant. For a power of 0.80 and an α error of 0.05, the estimated sample size needed would be 29 patients in each group (8, 19, 20).

All analyses were performed with SPSS software version 17.0 (SPSS Inc, Chicago, IL, USA). Continuous variables were analyzed using Student’s t-test or the Wilcoxon rank-sum test where applicable. Categorical data were tested using Fisher’s exact test or the chi-square test. The threshold for statistical significance was chosen as $P = 0.05$ in the 2-tailed tests.

**Ethics statement**
This study protocol was reviewed and approved by the institutional review board of Samsung Medical Center (IRB No.2007-04-049), and performed according to the Declaration of Helsinki. All subjects provided their written informed consent before participation.

**RESULTS**

**Baseline characteristics and procedural data**
From August 2007 to February 2009, a total of 218 patients were enrolled in the AT-STEMI trial, and 87 patients enrolled in the Samsung Medical Center were candidates for the MRI substudy. Of these, CE-MRI was not performed due to claustrophobia (n = 2) or metallic implant within the body (n = 1). Furthermore, 15 patients did not undergo CE-MRI because of hemodynamic instability after the enrollment (n = 6), or patient refusal (n = 9). After excluding inadequate MRI images from analysis (n = 2), CE-MRI data were ultimately available for 30 patients in the atorvastatin group and 37 patients in the control group. Overall subject characteristics including clinical presentations and initial laboratory findings are presented in Table 1. There was no significant difference in baseline clinical and laboratory characteristics between the two groups.

Table 2 shows the angiographic and procedural findings of the two groups. The atorvastatin group tended to have a lower grade of TIMI flow than the control group, but this difference was not statistically significant. Most patients of the two groups underwent implantation of stents in the culprit coronary arteries. Drug-eluting stents were used predominantly, with no difference between the study groups. The stent diameter and length were similar in the two groups. There were no significant differences in medication during hospitalization and follow-up period (Table 3).

**Angiographic, ECG, biochemical, and clinical outcomes**
No angiographic reflow, final TIMI flow grade, and final MBG...
Table 2. Angiographic and procedural findings

| Findings                        | Atorvastatin group (n = 30) | Control group (n = 37) | P   |
|--------------------------------|-----------------------------|------------------------|-----|
| Culprit vessel                  |                             |                        | 0.86|
| Left anterior descending artery, n (%) | 15 (50.0)                   | 21 (56.8)              |     |
| Left circumflex artery, n (%)   | 4 (13.3)                    | 5 (13.5)               |     |
| Right coronary artery, n (%)    | 11 (36.7)                   | 11 (29.7)              |     |
| Number of diseased vessels      |                             |                        | 0.97|
| 1                              | 16 (53.3)                   | 20 (54.1)              |     |
| 2                              | 8 (26.7)                    | 9 (24.3)               |     |
| 3                              | 6 (20.0)                    | 9 (24.3)               |     |
| Lesion type B2/C                |                             |                        | 0.94|
| Baseline TIMI flow grade        |                             |                        | 0.06|
| 0/1                            | 24 (80.0)                   | 22 (59.5)              |     |
| 2                              | 5 (16.7)                    | 6 (16.2)               |     |
| 3                              | 1 (3.3)                     | 9 (24.3)               |     |
| PCT type                       |                             |                        | 0.50|
| Balloon only                    |                             |                        |     |
| Stent                           | 30 (100.0)                  | 35 (94.6)              |     |
| Type of stent                   |                             |                        | 0.48|
| Bare-metal stent                |                             |                        |     |
| Drug-eluting stent              |                             |                        |     |
| Stent diameter (mm)             | 3.25 (3.0-3.5)              | 3.5 (3.0-3.5)          | 0.86|
| Stent length (mm)               | 24.0 (20.0-30.0)            | 24.0 (18.0-32.0)       | 0.72|

Data are expressed as n (%) or median (interquartile range).

Table 3. Medications

| Medications                      | Atorvastatin group (n = 30) | Control group (n = 37) | P   |
|---------------------------------|-----------------------------|------------------------|-----|
| During hospital stay            |                             |                        |     |
| Aspirin                         | 30 (100.0)                  | 37 (100.0)             | -   |
| Clopidogrel                     | 30 (100.0)                  | 36 (97.3)              | 1.00|
| β-blocker                       | 26 (86.7)                   | 36 (97.3)              | 0.17|
| ACE inhibitor/ARBs              | 27 (80.0)                   | 36 (97.3)              | 0.32|
| Glycoprotein IIb/IIIa inhibitor | 12 (40.0)                   | 12 (32.4)              | 0.52|
| Follow up at 1 month            |                             |                        |     |
| Aspirin                         | 30 (100.0)                  | 36 (97.3)              | 1.00|
| Clopidogrel                     | 30 (100.0)                  | 36 (97.3)              | 1.00|
| β-blocker                       | 26 (86.7)                   | 34 (91.9)              | 0.69|
| ACE inhibitor/ARBs              | 27 (80.0)                   | 34 (91.9)              | 1.00|
| Statin                          | 29 (96.7)                   | 37 (100.0)             | 0.26|
| Follow-up at 6 months           |                             |                        |     |
| Aspirin                         | 30 (100.0)                  | 36 (97.3)              | 1.00|
| Clopidogrel                     | 29 (96.7)                   | 35 (97.2)              | 1.00|
| β-blocker                       | 26 (86.7)                   | 31 (86.1)              | 1.00|
| ACE inhibitor/ARBs              | 28 (93.3)                   | 32 (88.9)              | 0.68|
| Statin                          | 28 (93.3)                   | 34 (94.4)              | 1.00|

Data are expressed as n (%), ACE, Angiotensin-converting enzyme; ARB, angiotensin-receptor blocker.

Table 4. Angiographic, ECG, biochemical and clinical outcomes

| Outcomes                          | Atorvastatin group (n = 30) | Control group (n = 37) | P   |
|-----------------------------------|-----------------------------|------------------------|-----|
| Angiographic no reflow            |                             |                        | 0.45|
| Final TIMI flow grade             |                             |                        | 0.09|
| 1                                 | 5 (16.7)                    | 3 (8.1)                |     |
| 2                                 | 8 (26.7)                    | 4 (10.8)               |     |
| 3                                 | 22 (73.3)                   | 33 (89.2)              |     |
| Final MBG                         |                             |                        | 0.43|
| 0/1                               | 11 (36.7)                   | 8 (22.2)               |     |
| 2                                 | 5 (16.7)                    | 8 (22.2)               |     |
| 3                                 | 14 (46.7)                   | 20 (55.6)              |     |
| Complete ST resolution at 60 min  |                             |                        | 0.79|
| Peak CK-MB (ng/mL)                | 226.3 ± 140.9 174.1 ± 147.3 | 0.15 |
| Major adverse cardiac events      |                             |                        |     |
| Death                             |                             |                        | 0.46|
| Heart failure or new-onset sustained hypotension | 7 (23.3) | 6 (16.2) |     |
| Readmission for left ventricular dysfunction | 1 (3.3) | 3 (8.1) | 0.62|

Data are expressed as n (%) or mean ± SD.

Table 5. Results of CE-MRI analysis

| Findings                          | Atorvastatin group (n = 30) | Control group (n = 37) | P   |
|-----------------------------------|-----------------------------|------------------------|-----|
| LVEDV (mL)                        | 115.0 (98.2-130.4)          | 123.7 (84.9-148.8)     | 0.37|
| LVESV (mL)                        | 49.8 (43.2-75.9)            | 66.0 (45.9-84.8)       | 0.36|
| LV Mass (g)                       | 121.1 (96.8-135.6)          | 123.5 (102.9-137.7)    | 0.28|
| LV ejection fraction (%)          | 49.9 (39.8-60.2)            | 46.3 (39.9-52.4)       | 0.56|
| Infarct size (% of LV)            | 19.0 (11.1-31.4)            | 16.3 (7.2-27.2)        | 0.27|
| Area at risk (% of LV)            | 31.6 (24.7-51.3)            | 28.2 (20.2-41.4)       | 0.25|
| Myocardial salvage index          | 37.1 (26.9-58.7)            | 46.9 (31.1-60.4)       | 0.46|
| Hemorrhagic infarction, n(%)      | 17 (56.7)                   | 18 (48.6)              | 0.51|
| MVO area (% of LV)                | 1.1 (0-1.97)                | 0.7 (0-1.8)            | 0.37|
| Transmurality                     | 10 (33.3)                   | 21 (56.8)              | 0.06|

Data are expressed as n (%) or median (interquartile range), LV, left ventricle; LVEDV, left ventricle end diastolic volume; LVESV, left ventricle end systolic volume; MVO, microvascular obstruction.

**CE-MRI findings**

There was no difference in the intervals from procedure to MRI between the groups (9.5 [6-18.3] vs. 8 [5-12.5], P = 0.17). Table 5 shows data analyzed from the cine, T2-weighted and CE-MRI of the atorvastatin and control group. The LV end diastolic volume, end systolic volume, and ejection fraction measured by MRI were similar in both groups. The primary end point, infarct size on CE-MRI after the atorvastatin pretreatment and procedure was not significantly different between the two groups (19% [11.1-31.4] vs. 16.3% [7.2-27.2], P = 0.27). Additionally, the myocardial salvage index (37.1% [26.9-58.7] vs. 46.9% [39.9-52.4], P = 0.46) and the extent of MVO (1.1% [0-1.97] vs. 0.7% [0-1.8], P = 0.37) were not lower in the atorvastatin group compared to the control group. There were no significant differences of the incidence of hemorrhagic (56.7% vs. 48.6%, P = 0.51) or transmural infarctions in both groups (33.3% vs. 56.8%, P = 0.06).
DISCUSSION

In this randomized study, we compared CE-MRI recordings to evaluate the efficacy of high dose atorvastatin loading followed by further medication for 5 days after PCI on the extent of myocardial infarction in patients undergoing primary PCI for STEMI. Our data indicate that infarction severity does not change after atorvastatin pretreatment in STEMI patients. There was no significant difference in the infarct size, AAR, MVO area, infarct transmurality, a frequency of hemorrhagic infarction, or the proportion of myocardial salvage between the atorvastatin group and controls. Moreover, post-procedural TIMI flow grade, MBG, complete ST-segment resolution at 60 min, and the peak CK-MB level was similar in both groups.

The AT-STEMI and STATIN STEMI trials report that high-dose atorvastatin pretreatment before PCI did not show significant improvement of clinical outcome (8, 22). However, these 2 trials have too few numbers of participants to draw conclusions regarding the clinical outcome including major adverse cardiac events. Although infarct size measured by SPECT was primary end point in the AT-STEMI trial, SPECT has low sensitivity in cases of small myocardial infarctions or non-transmural infarctions. Furthermore, the STATIN STEMI study showed that secondary end points such as MBG and complete ST segment resolution were improved in the atorvastatin group. In the AT-STEMI trial, the high-dose atorvastatin pretreatment group demonstrated absolutely 5.2% reduced incidence of major adverse cardiac events at 6 months (8). Considering these doubtful conclusions, larger randomized trials or more obvious surrogate parameters as primary end points are required to confirm the effects of atorvastatin pretreatment. Therefore, our study may have strengths with respect to performing a planned substudy using CE-MRI-derived infarct size as the primary end point. In addition, CE-MRI is a reliable tool to detect morphologic and functional sequelae of myocardial infarction and provide a broad range of pathophysiological information such as the presence of scars, edema, and the viability of myocardium. CE-MRI might demonstrate more concrete impacts of atorvastatin pretreatment on injured myocardium that are not detected by other diagnostic modalities.

Although statins are known to have anti-inflammatory, anti-thrombotic effects and also known to improve endothelial function and myocardial circulation (24, 25), atorvastatin pretreatment did not reduce infarct size measured by CE-MRI in the present study. Moreover, the myocardial salvage index, which is an attractive CE-MRI parameter from a pathophysiological point of view, was not different between the atorvastatin and control group. MVO and hemorrhagic infarction, which are known to be predictors of adverse LV remodeling, as well as the risk of cardiovascular events did not show any differences between the 2 groups (26, 27). Our findings were supported by another CE-MRI study. In the REPERATOR trial, Post et al. reported that pretreatment with atorvastatin in an acute myocardial infarction does not result in an improved cardiac function, microvascular perfusion, or decreased myocardial infarct size (23). Although the comprehensive analysis of CE-CMR such as MVO and hemorrhagic infarction and a slightly larger number of enrolled patients are advantages of our study over the REPERATOR trial, they elegantly performed serial CE-MRI studies within 1 day, at 1 week, and 3 months follow up. Based on the results of both studies, it seems unlikely that high dose atorvastatin pretreatment in patients undergoing PCI for STEMI can reduce injury of myocardium.

This ineffectiveness of atorvastatin pretreatment in STEMI patients might be explained by severe ischemic burden or injury which cannot be prevented or reduced by a single dose of atorvastatin before primary PCI. The interval between atorvastatin administration and reperfusion might be too short for atorvastatin to initiate its action since the median door-to-ballooning time was 81 min in the atorvastatin group (8, 20).

Our study has several limitations. First, the sample size is not large, although calculations were conducted by standard methods based upon preliminary data. Second, only patients suitable for MRI examination were included. Therefore, the number of enrolled patients in each group was different. Unstable patients with hemodynamic compromise or severe arrhythmia were excluded from the study, which may have caused selection bias. Third, the timing of CE-MRI was widely distributed. However, CE-MRI was done within 14 days after primary PCI in all patients and there was no significant difference in interval from the index procedure to obtaining MRI between the 2 groups. Moreover, we did not undergo follow up CE-MRI, which might be more closely related to final myocardial damage. Fourth, this was not a placebo-controlled study. However, the primary end point was assessed independently and blindly at the core laboratory, and therefore we believe that this study design has little effect on the results. Lastly, our study has broad inclusion criteria. Because of the small sample size, we could not perform the subgroup analysis on patients who have a short time from symptom onset to ballooning or who are present with anterior wall infarction, which might have a better outcome in the atorvastatin pretreatment group.

To conclude, in this CE-MRI substudy of AT-STEMI trial, a high dose atorvastatin pretreatment followed by 5 days of further treatment did not reduce the infarct size in in patients undergoing primary PCI for STEMI. The present study suggests that atorvastatin preloading does not improve clinical outcomes in patients with STEMI.

DISCLOSURE

All of the authors have no conflicts of interest to disclose.
AUTHOR CONTRIBUTION

Conception and coordination of the study: Hahn JY; Design of ethical issues: Hahn JY, Kim EK, Song YB; Acquisition of data: Kim EK, Hahn JY, Song YB, Chang SA, Choi JH, Choi SH, Lee SC; Data review: Kim EK, Hahn JY, Song YB, Chang SA, Choi JH, Choi SH, Lee SC, Choe YH; Statistical analysis: Kim EK, Song YB; Manuscript preparation: All authors; Manuscript approval: all authors.

ORCID

Eun Yyoung Kim http://orcid.org/0000-0002-7653-3503
Joo-Yong Hahn http://orcid.org/0000-0002-4412-377X
Young Bin Song http://orcid.org/0000-0002-2581-8891
Sung-A Chang http://orcid.org/0000-0001-8053-0068
Jin-Ho Choi http://orcid.org/0000-0002-5421-793X
Eun Kyoung Kim http://orcid.org/0000-0002-0304-6317
Sang-Chol Lee http://orcid.org/0000-0003-2176-0482
Yeong Hyeon Choe http://orcid.org/0000-0002-9983-048X
Joo-Yong Hahn http://orcid.org/0000-0002-8967-4305

REFERENCES

1. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver ME, Waters D, Zeiher A, Chairman BR, Leslie S, Stern T, et al.; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285: 1711-8.

2. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-7.

3. Patti G, Cannon CP, Murphy SA, Mega S, Pisters L, Fazio N, Giugliano G, Colombo A, Yoo KH, Jeong MH, Kim JS, et al. Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention: a collaborative patient-level meta-analysis of 13 randomized studies. Circulation 2011; 123: 1622-32.

4. Pisters L, Patti G, Nüsca A, Pritstipino G, Richichi G, Di Sciascio G; ARMYDA Investigators. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) study. Circulation 2006; 110: 674-8.

5. Briguori C, Visconti G, Focaccia A, Golia B, Chieffo A, Castelli A, Mussardo M, Mottorfano M, Ricciardelli R, Colombo A. Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Am Coll Cardiol 2009; 54: 2157-63.

6. Patti G, Pisters L, Colonna G, Miglionico M, Fischetti D, Sardella G, Montinaro A, Di Sciascio G. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 2007; 49: 1272-8.

7. Kim JW, Yun KH, Kim EK, Kim YC, Joe DY, Ko JS, Rhee SJ, Lee EM, Yoo NJ, Kim NH, et al. Effect of high dose rosuvastatin loading before primary percutaneous coronary intervention on infarct size in patients with ST-segment elevation myocardial infarction. Korean Circ J 2014; 44: 76-81.

8. Hahn JY, Kim HJ, Choi YJ, Ji SH, Kim HJ, Lee S, Ahn KJ, Song YB, Choi JH, Choi SH, et al. Effects of atorvastatin pretreatment on infarct size in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am Heart J 2011; 162: 1026-33.

9. Miller TD, Christian TF, Hopfenspienger MR, Hodge DO, Gersh BJ, Gibbons RJ. Infarct size after acute myocardial infarction measured by quantitative tomographic 99mTc sestamibi imaging predicts subsequent mortality. Circulation 1995; 92: 334-41.

10. Kim B, Fieno DS, Parrish TB, Harris K, Chen EL, Simonetti O, Bundy J, Finn J, Klocke FJ, Judd RM. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 1999; 100: 1992-2002.

11. Wagner A, Mahrholdt H, Holly TA, Elliott MD, Regenius M, Parker M, Klocke FJ, Bonow RO, Kim RJ, Judd RM. Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: an imaging study. Lancet 2003; 361: 374-9.

12. Chung KI, Chung TS, White RD, Weimann HJ, Lim TH, Choi BI, Suh JH. Viable myocardium in reperfused acute myocardial infarction: rest and stress first-pass rm imaging. J Korean Med Sci 2001; 16: 294-302.

13. Perazzozi Marra M, Lima JA, Iliceto S. MRI in acute myocardial infarction. Eur Heart J 2011; 32: 284-93.

14. Eitel I, Desch S, Fuernau G, Hildebrand L, Guterblt M, Schuler G, Thiele H. Prognostic significance and determinants of myocardial salvage assessed by cardiovascular magnetic resonance in acute reperfused myocardial infarction. J Am Coll Cardiol 2010; 55: 2479-89.

15. de Waha S, Desch S, Eitel I, Fuernau G, Zachrau J, Gutberlet M, Schuler G, Thiele H. Impact of early vs. late microvascular obstruction assessed by magnetic resonance imaging on long-term outcome after ST-elevation myocardial infarction: a comparison with traditional prognostic markers. Eur Heart J 2010; 31: 2660-8.

16. van’t Hof AW, Liem A, Boer MJ, Zijlstra F. Clinical value of 12-lead electrocardiogram after successful reperfusion therapy for acute myocardial infarction. Zuwolle Myocardial infarction Study Group. Lancet 1997; 350: 615-9.

17. van’t Hof AW, Liem A, Suryapranata H, Hoornije JC, de Boer MJ, Zijlstra F. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zuwolle Myocardial Infarction Study Group. Circulation 1998; 97: 2302-6.

18. O’Regan DP, Ariff B, Newirth C, Tan Y, Durighel G, Cook SA. Assessment of severe reperfusion injury with 2T2 cardiac MRI in patients with acute myocardial infarction. Heart 2010; 96: 1885-91.

19. Xu J, Song YB, Hahn JY, Chang SA, Lee SC, Choe YH, Choi SH, Choi JH, Lee SH, Oh JY, et al. Comparison of magnetic resonance imaging findings in non-ST-segment elevation versus ST-segment elevation myocardial infarction patients undergoing early invasive intervention. Int J Cardiovasc Imaging 2012; 28: 1487-97.
20. Song YB, Hahn JY, Gwon HC, Chang SA, Lee SC, Choe YH, Choi SH, Choi JH, Lee SH, Oh JK. A high loading dose of clopidogrel reduces myocardial infarct size in patients undergoing primary percutaneous coronary intervention: a magnetic resonance imaging study. Am Heart J 2012; 163: 500-7.

21. Hahn JY, Gwon HC, Choe YH, Rhee I, Choi SH, Choi JH, Lee SH, Hong KP, Park JE. Effects of balloon-based distal protection during primary percutaneous coronary intervention on early and late infarct size and left ventricular remodeling: a pilot study using serial contrast-enhanced magnetic resonance imaging. Am Heart J 2007; 153: 665.e1-8.

22. Kim JS, Kim J, Choi D, Lee CJ, Lee SH, Ko YG, Hong MK, Kim BK, Oh SJ, Jeon DW, et al. Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial. JACC Cardiovasc Interv 2010; 3: 332-9.

23. Post S, Post MC, van den Branden BJ, Eefting FD, Goumans MJ, Stella PR, van Es HW, Wildergh TX, Rensing BJ, Doevendans PA. Early statin treatment prior to primary PCI for acute myocardial infarction: REPER-ATOR, a randomized placebo-controlled pilot trial. Catheter Cardiovasc Interv 2012; 80: 756-65.

24. Wassmann S, Faul A, Hennen B, Scheller B, Böhmer M, Nickenig G. Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition on coronary endothelial function. Circ Res 2003; 93: e98-103.

25. Hinoi T, Matsuo S, Tadokoro F, Tsujiyama S, Yamakido M. Acute effect of atorvastatin on coronary circulation measured by transthoracic Doppler echocardiography in patients without coronary artery disease by angiography. Am J Cardiol 2005; 96: 89-91.

26. Mather AN, Fairbairn TA, Ball SG, Greenwood JP, Plein S. Reperfusion haemorrhage as determined by cardiovascular MRI is a predictor of adverse left ventricular remodelling and markers of late arrhythmic risk. Heart 2011; 97: 453-9.

27. Tarantini G, Razzolini R, Cacciavillani L, Bilato C, Sarais C, Corbetti F, Marra MP, Napodano M, Ramondo A, Iliceto S. Influence of transmurality, infarct size, and severe microvascular obstruction on left ventricular remodeling and function after primary coronary angioplasty. Am J Cardiol 2008; 98: 1033-40.